{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:28:25Z","timestamp":1761593305331,"version":"build-2065373602"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rdc.2025.07.012","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T04:46:51Z","timestamp":1757825211000},"page":"719-735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Promising Treatments in Juvenile Dermatomyositis"],"prefix":"10.1016","volume":"51","author":[{"given":"Belina Y.","family":"Yi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercy","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2025.07.012_bib1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.11122","article-title":"US incidence of juvenile dermatomyositis, 1995-1998: results from the national institute of arthritis and musculoskeletal and skin diseases registry","volume":"49","author":"Mendez","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/rheumatology\/kel099","article-title":"The juvenile dermatomyositis national registry and repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr","volume":"45","author":"McCann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","article-title":"The clinical phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Shah","year":"2013","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.rdc.2025.07.012_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J Intern Med"},{"key":"10.1016\/j.rdc.2025.07.012_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3476(64)80325-5","article-title":"Dermatomyositis","volume":"64","author":"Bitnum","year":"1964","journal-title":"J Pediatr"},{"key":"10.1016\/j.rdc.2025.07.012_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.27218","article-title":"Mortality outcomes in pediatric rheumatology in the US","volume":"62","author":"Hashkes","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/acr.24466","article-title":"Parent perspectives on addressing emotional health for children and young adults with juvenile myositis","volume":"73","author":"Ardalan","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2025.07.012_bib9","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.11211","article-title":"Bone mineral density in juvenile dermatomyositis: assessment using dual x-ray absorptiometry","volume":"48","author":"Stewart","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","article-title":"Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity","volume":"87","author":"Bingham","year":"2008","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.rdc.2025.07.012_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/art.24343","article-title":"Health-related quality of life of patients with juvenile dermatomyositis: results from the pediatric rheumatology International Trials Organisation multinational quality of life cohort study","volume":"61","author":"Apaz","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2025.07.012_bib13","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.07.012_bib14","first-page":"S118","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and patient\/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)\/childhood health assessment questionnaire (C-HAQ)","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2025.07.012_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/ptj\/72.2.115","article-title":"Intrarater reliability of manual muscle test (medical research council scale) grades in Duchenne's muscular dystrophy","volume":"72","author":"Florence","year":"1992","journal-title":"Phys Ther"},{"key":"10.1016\/j.rdc.2025.07.012_bib16","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1002\/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8","volume":"42","author":"Lovell","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib18","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/rheumatology\/kem179","article-title":"The cutaneous assessment tool: development and reliability in juvenile idiopathic inflammatory myopathy","volume":"46","author":"Huber","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib19","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.40064","volume":"69","author":"Aggarwal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.40060","volume":"69","author":"Rider","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib21","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/rheumatology\/kex226","article-title":"2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects","volume":"56","author":"Rider","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib22","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/annrheumdis-2012-202915","article-title":"Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis","volume":"73","author":"Malattia","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.07.012_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1749-6632.2009.04498.x","article-title":"MRI in juvenile idiopathic arthritis and juvenile dermatomyositis","volume":"1154","author":"Gardner-Medwin","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.rdc.2025.07.012_bib24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.07.012_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2025.07.012_bib26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/acr.20695","article-title":"Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference","volume":"64","author":"Huber","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2025.07.012_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood Arthritis and rheumatology research alliance Consensus clinical treatment plans for Juvenile dermatomyositis with persistent skin rash","volume":"44","author":"Huber","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-016-0134-0","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease","volume":"15","author":"Kim","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.rdc.2025.07.012_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.07.012_bib30","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14397595.2020.1718866","article-title":"Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update","volume":"30","author":"Kobayashi","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib32","first-page":"435","article-title":"Systemic rheumatic disorders (\u2018collagen disease\u2019) in childhood: lupus erythematosus, anaphylactoid purpura, dermatomyositis, and scleroderma. I","volume":"17","author":"Hanson","year":"1967","journal-title":"Bull Rheum Dis"},{"key":"10.1016\/j.rdc.2025.07.012_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0026-0495(74)90113-9","article-title":"Mechanism of action of glucocorticoids","volume":"23","author":"Thompson","year":"1974","journal-title":"Metabolism"},{"key":"10.1016\/j.rdc.2025.07.012_bib34","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/00002281-199002030-00016","article-title":"Steroids","volume":"2","author":"Kimberly","year":"1990","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib35","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3899\/jrheum.090953","article-title":"Treatment approaches to juvenile dermatomyositis (JDM) across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey","volume":"37","author":"Stringer","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib37","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.20278","article-title":"Toward a better understanding of methotrexate","volume":"50","author":"Kremer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.rdc.2025.07.012_bib39","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1093\/rheumatology\/keac107","article-title":"Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study","volume":"61","author":"Dabbak","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib40","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/art.22157","article-title":"Antimalarial agents: closing the gate on toll-like receptors?","volume":"54","author":"Lafyatis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib41","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ncprheum0292","article-title":"Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling","volume":"2","author":"Kyburz","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib42","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1093\/rheumatology\/keab089","article-title":"Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers","volume":"60","author":"Varnier","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib43","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semarthrit.2018.03.016","article-title":"Medications received by patients with juvenile dermatomyositis","volume":"48","author":"Kishi","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib44","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archderm.138.9.1231","article-title":"Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus","volume":"138","author":"Pelle","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaad.2017.09.061","article-title":"Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study","volume":"78","author":"Mittal","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/FPC.0000000000000010","article-title":"PharmGKB summary: mycophenolic acid pathway","volume":"24","author":"Lamba","year":"2014","journal-title":"Pharmacogenet Genom"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2025.07.012_bib47","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.rdc.2025.07.012_bib48","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/acr.20269","article-title":"Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis","volume":"62","author":"Rouster-Stevens","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2025.07.012_bib49","doi-asserted-by":"crossref","first-page":"SI163","DOI":"10.1093\/rheumatology\/keac404","article-title":"Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies","volume":"62","author":"Varnier","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.rdc.2025.07.012_bib51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0952-7915(92)90024-9","article-title":"FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond","volume":"4","author":"Siekierka","year":"1992","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.rdc.2025.07.012_bib52","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s10067-008-0973-2","article-title":"Treatment of refractory juvenile dermatomyositis with tacrolimus","volume":"27","author":"Hassan","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib53","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00431-004-1497-7","article-title":"Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A","volume":"163","author":"Yamada","year":"2004","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.rdc.2025.07.012_bib54","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib55","article-title":"An adolescent case of Anti-MDA5 antibody-positive juvenile dermatomyositis with interstitial lung disease successfully treated by multitarget therapy avoiding cyclophosphamide: a case report and literature review","volume":"16","author":"Yokoyama","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.rdc.2025.07.012_bib56","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0049-0172(83)90016-1","article-title":"Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases","volume":"12","author":"Kovarsky","year":"1983","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib57","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.40418","article-title":"Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling","volume":"70","author":"Deakin","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib58","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/rheumatology\/keh082","article-title":"Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety","volume":"43","author":"Riley","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u2018ProDERM study\u2019)","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.rdc.2025.07.012_bib60","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.intimp.2005.11.016","article-title":"The role of high-dose immune globulin intravenous in the treatment of dermatomyositis","volume":"6","author":"Dalakas","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.rdc.2025.07.012_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102997","article-title":"Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: a systematic review and meta-analysis","volume":"21","author":"Goswami","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rdc.2025.07.012_bib62","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1136\/ard.2011.153718","article-title":"Efficacy of intravenous Ig therapy in juvenile dermatomyositis","volume":"70","author":"Lam","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.07.012_bib63","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib64","article-title":"Clinical improvement in early onset interstitial lung disease using rituximab in children with antimelanoma differentiation-associated gene 5-Positive juvenile dermatomyositis","author":"Peskin","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib65","first-page":"1046","article-title":"Advances in juvenile dermatomyositis: pathophysiology, diagnosis, treatment and interstitial lung Diseases-A narrative review","volume":"11","author":"Kobayashi","year":"2024","journal-title":"Child Basel Switz"},{"key":"10.1016\/j.rdc.2025.07.012_bib66","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10067-023-06740-3","article-title":"Biologic drugs in the treatment of juvenile dermatomyositis: a literature review","volume":"43","author":"Sener","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib67","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12969-022-00785-5","article-title":"Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the childhood arthritis and rheumatology research alliance","volume":"21","author":"Sherman","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.rdc.2025.07.012_bib68","article-title":"Efficacy and safety of subcutaneous abatacept + standard treatment for active idiopathic inflammatory myopathy: phase III randomised controlled trial","author":"Aggarwal","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib69","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0002-9440(10)65141-3","article-title":"Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies","volume":"155","author":"Murata","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.rdc.2025.07.012_bib70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/clim.1999.4743","article-title":"Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells","volume":"92","author":"Nagaraju","year":"1999","journal-title":"Clin Immunol Orlando Fla"},{"key":"10.1016\/j.rdc.2025.07.012_bib71","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/art.42450","article-title":"Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy","volume":"75","author":"Curiel","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib72","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib73","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J Pediatr"},{"key":"10.1016\/j.rdc.2025.07.012_bib74","article-title":"Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-Year-Old girl","volume":"2020","author":"Sukumaran","year":"2020","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14976","article-title":"The effects of infliximab in treating idiopathic inflammatory myopathies: a review article","volume":"34","author":"Ge","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.rdc.2025.07.012_bib76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13075-020-02164-5","article-title":"Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients","volume":"22","author":"Campanilho-Marques","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2025.07.012_bib77","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","article-title":"Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis","volume":"47","author":"Riley","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib78","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/jid.2011.281","article-title":"It's all about position: the basal layer of human epidermis is particularly susceptible to different types of sunlight-induced DNA damage","volume":"132","author":"Halliday","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib79","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/art.37985","article-title":"Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis","volume":"65","author":"Shah","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib80","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.23840","article-title":"Association of short-term ultraviolet radiation exposure and disease severity in juvenile dermatomyositis: results from the childhood arthritis and rheumatology research alliance legacy registry","volume":"71","author":"Neely","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2025.07.012_bib81","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/acr.24059","article-title":"Association of ultraviolet radiation exposure with dermatomyositis in a national myositis patient registry","volume":"72","author":"Parks","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2025.07.012_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102782","article-title":"Bone health in idiopathic inflammatory myopathies","volume":"20","author":"Cox","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rdc.2025.07.012_bib83","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40272-017-0219-3","article-title":"Protecting bone health in pediatric rheumatic diseases: pharmacological considerations","volume":"19","author":"Zhang","year":"2017","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.rdc.2025.07.012_bib84","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/rheumatology\/kew026","article-title":"Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis","volume":"55","author":"Habers","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib85","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/rheumatology\/38.7.608","article-title":"Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study","volume":"38","author":"Alexanderson","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib86","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.22780","article-title":"Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis","volume":"57","author":"Alexanderson","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.012_bib87","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/030097400447679","article-title":"The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis","volume":"29","author":"Alexanderson","year":"2000","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib88","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s10067-022-06281-1","article-title":"Physical exercise for dermatomyositis and polymyositis: a systematic review and meta-analysis","volume":"41","author":"da Silva","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib89","first-page":"413","article-title":"Mental health in paediatric and adult myositis-related diseases: current state of research, interventions, and future steps from the MIHRA psychological impact scientific working group","volume":"42","author":"Lanis","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib90","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12969-017-0214-9","article-title":"Mental health care for youth with rheumatologic diseases - bridging the gap","volume":"15","author":"Davis","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.rdc.2025.07.012_bib91","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12969-021-00503-7","article-title":"Engaging patients and parents to improve mental health intervention for youth with rheumatological disease","volume":"19","author":"Fawole","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.rdc.2025.07.012_bib92","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14656566.2024.2392021","article-title":"Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons","volume":"25","author":"Wallwork","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.rdc.2025.07.012_bib93","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.012_bib94","first-page":"4732","article-title":"Approach to janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers","volume":"64","author":"Sherman","year":"2025","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.rdc.2025.07.012_bib95","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/keac399","article-title":"Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis","volume":"62","author":"Huang","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib96","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-023-03170-z","article-title":"Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China","volume":"25","author":"Zhang","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2025.07.012_bib97","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1093\/rheumatology\/keae392","article-title":"Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis","volume":"63","author":"Papadopoulou","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib99","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.rdc.2025.07.012_bib100","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2025.07.012_bib101","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-Targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib102","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2025.07.012_bib103","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/art.42526","article-title":"The type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis","volume":"75","author":"Tabata","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib104","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2025.07.012_bib105","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib106","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/rheumatology\/keab601","article-title":"Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response","volume":"61","author":"Lerkvaleekul","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.012_bib107","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","article-title":"Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment","volume":"160","author":"Shaw","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib108","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2024.07.1491","article-title":"Anifrolumab in recalcitrant cutaneous dermatomyositis: a multicenter retrospective cohort study","volume":"91","author":"Shaw","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.012_bib109","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ced\/llae476","article-title":"Anifrolumab use in refractory dermatomyositis: a case report and literature review","volume":"50","author":"Claudio-Oliva","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.rdc.2025.07.012_bib110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","article-title":"Refractory dermatomyositis responsive to anifrolumab","volume":"43","author":"Ang","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.rdc.2025.07.012_bib114","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2174\/0929867329666220825161603","article-title":"Recent advances on Type-2 cannabinoid (CB2) receptor agonists and their therapeutic potential","volume":"30","author":"Gasperi","year":"2023","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.rdc.2025.07.012_bib115","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11481-013-9445-9","article-title":"Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation","volume":"8","author":"Rom","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.rdc.2025.07.012_bib116","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"J Invest Dermatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:21:56Z","timestamp":1761592916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0889857X25000596"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.012","relation":{},"ISSN":["0889-857X"],"issn-type":[{"type":"print","value":"0889-857X"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Promising Treatments in Juvenile Dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}